Innate Pharma files its 2022 universal registration document (document d'enregistrement universel) and 2022 annual report on Form 20-F

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2022 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 6, 2023. It can be downloaded (in French) on the Company’s website and on the AMF’s website. 

The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2022 with the United States Securities and Exchange Commission (“SEC”). It can be also be accessed on the Company’s website and on the SEC’s website.